Boltz PBC develops frontier artificial intelligence models and computing infrastructure for biology and chemistry, helping scientists design molecules and advance scientific discovery. Its products support biomolecular modeling and design, including small-molecule discovery, protein design, and structure prediction. The company’s model portfolio includes BoltzMol-1, BoltzProt-1, Boltz-2, and BoltzGen, with some models identified as open source.

Scientists and organizations can access these capabilities through Boltz API and Boltz Lab, as well as Python and TypeScript tools. Boltz offers fast inference for designing proteins and small molecules, and provides fine-tuning to adapt models to proprietary data, targets, and assays. Deployment options include multi-tenant, single-tenant, and on-premise environments; the site also notes SOC 2 Type 1 verification.

Boltz reports adoption by more than 100,000 scientists, over 1,000 companies, and 20 leading pharmaceutical companies, alongside more than five million downloads. The company also pursues strategic collaborations in drug and ingredient discovery, and invites research partners and prospective employees to connect.